Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Breast Cancer | Review

The role of Th17 cells in the pathogenesis and treatment of breast cancer

Authors: Vahid Karpisheh, Majid Ahmadi, Kazem Abbaszadeh-Goudarzi, Mehran Mohammadpour Saray, Asal Barshidi, Hamed Mohammadi, Mehdi Yousefi, Farhad Jadidi-Niaragh

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Breast cancer is a severe problem worldwide due to an increase in mortality and prevalence among women. Despite early diagnostic procedures as well as advanced therapies, more investigation is required to find new treatment targets. Various factors and mechanisms, such as inflammatory conditions, can play a crucial role in cancer progression. Among them, Th17 cells are identified as effective CD4+ T cells that play an essential role in autoimmune diseases and inflammation which may be associated with anti-tumor responses. In addition, Th17 cells are one of the main factors involved in cancer, especially breast cancer via the inflammatory process. In tumor immunity, the exact mechanism of Th17 cells is not entirely understood and seems to have a dual function in tumor development. Various studies have reported that cytokines secreted by Th17 cells are in close relation to cancer stem cells and tumor microenvironment. Therefore, they play a critical role in the growth, proliferation, and invasion of tumor cells. On the other hand, most studies have reported that T cells suppress the growth of tumor cells by the induction of immune responses. In patients with breast cancer compared to normal individuals, various studies have been reported that the Th17 population dramatically increases in peripheral blood which results in cancer progression. It seems that Th17 cells by creating inflammatory conditions through the secretion of cytokines, including IL-22, IL-17, TNF-α, IL-21, and IL-6, can significantly enhance breast cancer progression. Therefore, to identify the mechanisms and factors involved in the activation and development of Th17 cells, they can provide an essential role in preventing breast cancer progression. In the present review, the role of Th17 cells in breast cancer progression and its therapeutic potential was investigated.
Literature
1.
Ishaque N, Asad M. Clinicopathological characteristics of breast carcinoma in premenopausal women. J Islamabad Med Dental College. 2019;8(4):193–7.CrossRef
2.
Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A. Lower A risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: EpiGEICAM case-control study. PLoS ONE. 2015;10(5):e0126096.PubMedPubMedCentralCrossRef
3.
Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, Mohar A, Bargalló E, Meneses A, Cazap E, Gomez H, López-Carrillo L, Chávarri-Guerra Y. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013;18(12):1298.PubMedPubMedCentralCrossRef
4.
Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28(20):3366–79.PubMedCrossRef
5.
Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. The Breast. 2013;22:S50–6.PubMedCrossRef
6.
Karpisheh V, Joshi N, Zekiy AO, Beyzai B, Hojjat-Farsangi M, Namdar A, Edalati M, Jadidi-Niaragh F. EP4 receptor as a novel promising therapeutic target in colon cancer: running title: EP4 receptor in colon cancer. Pathol-Res Pract. 2020;216:153247.PubMedCrossRef
7.
Karpisheh V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, Yousefi B, Jadidi-Niaragh F. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins Other Lipid Mediators. 2019;144:106338.PubMedCrossRef
8.
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:1.CrossRef
9.
Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. The Breast. 2007;16:27–33.CrossRef
10.
Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010;184(3):1630–41.PubMedCrossRef
11.
Nam J-S, Terabe M, Kang M-J, Chae H, Voong N, Yang Y-a, Laurence A, Michalowska A, Mamura M, Lonning S. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 2008;68(10):3915–23.PubMedPubMedCentralCrossRef
12.
Neel J-C, Humbert L, Lebrun J-J. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. Int Scholarly Res Notices. 2012;2012:1.
13.
Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, Inoue N. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol. 2008;180(11):7175–83.PubMedCrossRef
14.
Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, Soumelis V. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human T H-17 responses. Nat Immunol. 2008;9(6):650.PubMedCrossRef
15.
Manel N, Unutmaz D, Littman DR. The differentiation of human T H-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol. 2008;9(6):641.PubMedPubMedCentralCrossRef
16.
Zhou Z, Sun W, Liang Y, Gao Y, Kong W, Guan Y, Feng J, Wang X. Fenofibrate inhibited the differentiation of T helper 17 cells in vitro. PPAR Res. 2012;2012:1.
17.
Karpisheh V, Mousavi SM, Sheykholeslami PN, Fathi M, Mohammadpour Saray M, Aghebati-Maleki L, Jafari R, Zolbanin NM, Jadidi-Niaragh F. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 2021;119132.
18.
Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F. Development, cytokine profile and function of human interleukin 17–producing helper T cells. Nat Immunol. 2007;8(9):950–7.PubMedCrossRef
19.
20.
Weaver CT, Hatton RD. Interplay between the TH 17 and T Reg cell lineages: a (co-) evolutionary perspective. Nat Rev Immunol. 2009;9(12):883–9.PubMedCrossRef
21.
Chen Z, Laurence A, O’Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. In: Elsevier, 2007; 400–408.
22.
23.
Guéry L, Hugues S. Th17 cell plasticity and functions in cancer immunity. BioMed Res Int. 2015;2015:1.CrossRef
24.
Wang S, Li Z, Hu G. Prognostic role of intratumoral IL-17A expression by immunohistochemistry in solid tumors: a meta-analysis. Oncotarget. 2017;8(39):66382.PubMedPubMedCentralCrossRef
25.
Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, J Am Soc Hematol. 2008;112(2):362–73.
26.
Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys. 2012;62(1):153–9.PubMedCrossRef
27.
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMedCrossRef
28.
Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updat Surg. 2017;69(3):313–7.CrossRef
29.
Reyna C, Lee MC. Breast cancer in young women: special considerations in multidisciplinary care. J Multidiscip Healthc. 2014;7:419.PubMedPubMedCentral
30.
31.
Coughlin SS, Smith SA. The impact of the natural, social, built, and policy environments on breast cancer. J Environ Health Sci. 2015;1(3):1.
32.
Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):1–19.CrossRef
33.
Podkowa N, Komasińska P, Roszak M, Gryczka R, Grodecka-Gazdecka S, Łacka K. Health behaviours among women diagnosed with breast tumours. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. 2014;37(219):153–8.
34.
Kruk J. Intensity of recreational physical activity in different life periods in relation to breast cancer among women in the region of Western Pomerania. Contemp Oncol. 2012;16(6):576.
35.
Barlow WE, Lehman CD, Zheng Y, Ballard-Barbash R, Yankaskas BC, Cutter GR, Carney PA, Geller BM, Rosenberg R, Kerlikowske K. Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst. 2002;94(15):1151–9.PubMedCrossRef
36.
37.
Alnoqaidan EA, Rubui RM, Alshehri AS, Aljarba ZFA, Alhelali NNG, Alda-blan AS, Albalawi AZ, Alamri AHA, Shaa-ban AS, Albaghdadi AT. An overview on diagnosis and management approach of breast cancer.
38.
Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4(2):117–32.PubMedPubMedCentralCrossRef
39.
Matsen CB, Neumayer LA. Breast cancer: a review for the general surgeon. JAMA Surg. 2013;148(10):971–80.PubMedCrossRef
40.
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929.PubMedPubMedCentral
41.
42.
Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol. 2000;165(11):6107–15.PubMedCrossRef
43.
44.
Laprevotte E, Bastid J, Cochaud S, Giustiniani J, Philippe M, Frewer KA, Sanders AJ, Jiang WG, Bensussan A, Alberici G. Interleukin-17B promotes chemoresistance of breast tumors through ERK1/2 anti-apoptotic pathway. In: AACR; 2015.
45.
Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009;2(5):403–11.PubMedPubMedCentralCrossRef
46.
Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin J-J, Garrone P, Garcia E, Saeland S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183(6):2593–603.PubMedCrossRef
47.
Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, Cosmi L, Lunardi C, Annunziato F, Romagnani S. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115(2):335–43.PubMedCrossRef
48.
Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519–28.PubMedPubMedCentralCrossRef
49.
Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271–9.PubMedPubMedCentralCrossRef
50.
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787–98.PubMedPubMedCentralCrossRef
51.
Mitsdoerffer M, Lee Y, Jäger A, Kim H-J, Korn T, Kolls JK, Cantor H, Bettelli E, Kuchroo VK. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci. 2010;107(32):14292–7.PubMedPubMedCentralCrossRef
52.
Munegowda MA, Deng Y, Mulligan SJ, Xiang J. Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother. 2011;60(10):1473.CrossRef
53.
Ronchi F, Basso C, Preite S, Reboldi A, Baumjohann D, Perlini L, Lanzavecchia A, Sallusto F. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells. Nat Commun. 2016;7(1):1–11.CrossRef
54.
Pang B, Zhen Y, Hu C, Ma Z, Lin S, Yi H. Myeloid-derived suppressor cells shift Th17/Treg ratio and promote systemic lupus erythematosus progression through arginase-1/miR-322-5p/TGF-β pathway. Clin Sci. 2020;134(16):2209–22.CrossRef
55.
Shahid A, Bharadwaj M. The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. Immunol Lett. 2019;213:9–20.PubMedCrossRef
56.
Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HHW. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 2013;63(2):225–33.PubMedCrossRef
57.
Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.PubMedPubMedCentralCrossRef
58.
Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177(1):566–73.PubMedCrossRef
59.
Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173–7.PubMedCrossRef
60.
Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146–55.PubMedPubMedCentralCrossRef
61.
Alizadeh D, Katsanis E, Larmonier N. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer. Clin Dev Immunol. 2013;2013:1.CrossRef
62.
Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S. Recent advances in understanding the molecular mechanisms of the development and function of T h17 cells. Genes Cells. 2013;18(4):247–65.PubMedPubMedCentralCrossRef
63.
Yang X-P, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, Hirahara K, Sun H-W, Wei L, Vahedi G. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011;12(3):247–54.PubMedPubMedCentralCrossRef
64.
Chen Z, Tato CM, Muul L, Laurence A, O’Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56(9):2936–46.PubMedPubMedCentralCrossRef
65.
Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor β–induced inhibition of T helper type 1 differentiation. J Exp Med. 2002;195(11):1499–505.PubMedPubMedCentralCrossRef
66.
Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-β inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 2000;165(9):4773–7.PubMedCrossRef
67.
Hirota K, Martin B, Veldhoen M. Development, regulation and functional capacities of Th17 cells. In: Springer, 2010;3–16.
68.
Schumann J, Muller U, Blessing M. TGF-β signaling in T cells is not essential for Th17 cell development in the mouse. J Biol Regul Homeost Agents. 2012;26(3):357–66.PubMed
69.
Sonderegger I, Kisielow J, Meier R, King C, Kopf M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol. 2008;38(7):1833–8.PubMedCrossRef
70.
Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory TH 17 cells. Nature. 2007;448(7152):484–7.PubMedPubMedCentralCrossRef
71.
Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 2005;5(9):688–98.PubMedCrossRef
72.
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448(7152):480–3.PubMedCrossRef
73.
Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967–74.PubMedCrossRef
74.
Karpisheh V, Afjadi JF, Afjadi MN, Haeri MS, Sough TSA, Asl SH, Edalati M, Atyabi F, Masjedi A, Hajizadeh F. Inhibition of HIF-1α/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells. Int J Biol Macromol. 2021;167:1006–19.PubMedCrossRef
75.
Rostamzadeh D, Razavi SR, Esmaeili S, Dolati S, Ahmahi M, Sadreddini S, Jadidi-Niaragh F, Yousefi M. Application of nanoparticle technology in the treatment of systemic lupus erythematous. Biomed Pharmacother. 2016;83:1154–63.PubMedCrossRef
76.
Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun HW, Kanno Y, Powrie F, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32(5):605–15.PubMedPubMedCentralCrossRef
77.
Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282(13):9358–63.PubMedCrossRef
78.
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti–interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9.PubMedCrossRef
79.
Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheumatic Dis. 2013;72(suppl 2):iii116–23.CrossRef
80.
Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597–605.PubMedCrossRef
81.
Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen Y-K, Doyle MK, Mendelsohn AM. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9.PubMedCrossRef
82.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.PubMedCrossRef
83.
Gocke AR, Cravens PD, Ben L-H, Hussain RZ, Northrop SC, Racke MK, Lovett-Racke AE. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol. 2007;178(3):1341–8.PubMedCrossRef
84.
Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE. T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells. Proc Natl Acad Sci. 2001;98(26):15137–42.PubMedPubMedCentralCrossRef
85.
Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17–producing T cells. Nat Immunol. 2006;7(9):929–36.PubMedCrossRef
86.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, Wang Y, Hood L, Zhu Z, Tian Q. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41.PubMedPubMedCentralCrossRef
87.
Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, Blumenschein WM, McClanahan T, Brombacher F, Hurst SD. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204(1):161–70.PubMedPubMedCentralCrossRef
88.
Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol. 2007;179(3):1423–6.PubMedCrossRef
89.
Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178(11):6730–3.PubMedCrossRef
90.
Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371–81.PubMedCrossRef
91.
92.
Baharlou R, Atashzar MR, Vasmehjani AA, Rahimi E, Khoshmirsafa M, Seif F, Mahdiyar M. Reduced levels of T-helper 17-associated cytokines in the serum of patients with breast cancer: indicators for following the course of disease. Central-Eur J Immunol. 2016;41(1):78.CrossRef
93.
Du J-W, Xu K-Y, Fang L-Y, Qi X-L. Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep. 2012;6(5):1099–102.PubMedCrossRef
94.
Kim K, Kim G, Kim J-Y, Yun HJ, Lim S-C, Choi HS. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis. 2014;35(6):1352–61.PubMedCrossRef
95.
Wang J, Cai D, Ma B, Wu G, Wu J. Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. J Int Med Res. 2011;39(3):691–701.PubMedCrossRef
96.
Benevides L, Cardoso CRB, Tiezzi DG, Marana HRC, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013;43(6):1518–28.PubMedCrossRef
97.
Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F. Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology. 2016;5(1):e1055444.PubMedCrossRef
98.
Ma K, Yang L, Shen R, Kong B, Chen W, Liang J, Tang G, Zhang B. Th17 cells regulate the production of CXCL1 in breast cancer. Int Immunopharmacol. 2018;56:320–9.PubMedCrossRef
99.
Zumwalde NA, Haag JD, Gould MN, Gumperz JE. Mucosal associated invariant T cells from human breast ducts mediate a Th17-skewed response to bacterially exposed breast carcinoma cells. Breast Cancer Res. 2018;20(1):1–14.CrossRef
100.
Avalos-Navarro G, Muñoz-Valle JF, Daneri-Navarro A, Quintero-Ramos A, Franco-Topete RA, de Jesus M-M, Oceguera-Villanueva A, Bautista-Herrera LA, Topete-Camacho A, Del Toro-Arreola A. Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile. Clin Exp Med. 2019;19(3):385–91.PubMedCrossRef
101.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8.PubMedPubMedCentralCrossRef
102.
Kim G, Khanal P, Lim S-C, Yun HJ, Ahn S-G, Ki SH, Choi HS. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. Carcinogenesis. 2013;34(2):341–50.PubMedCrossRef
103.
Huang SC, Wei PC, Hwang-Verslues WW, Kuo WH, Jeng YM, Hu CM, Shew JY, Huang CS, Chang KJ, Lee EYH. TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB. EMBO Mol Med. 2017;9(12):1660–80.PubMedPubMedCentralCrossRef
104.
Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, Lee V, Jin H, Wang M, Wright JA. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother. 2010;59(6):805–17.PubMedCrossRef
105.
Jiang Z, Chen J, Du X, Cheng H, Wang X, Dong C. IL-25 blockade inhibits metastasis in breast cancer. Protein Cell. 2017;8(3):191–201.PubMedCrossRef
106.
Faucheux L, Grandclaudon M, Perrot-Dockès M, Sirven P, Berger F, Hamy AS, Fourchotte V, Vincent-Salomon A, Mechta-Grigoriou F, Reyal F. A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. Oncoimmunology. 2019;8:e1624130.PubMedPubMedCentralCrossRef
107.
Ma M, Huang W, Kong D. IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3. Int Immunopharmacol. 2018;59:148–56.PubMedCrossRef
108.
Pawlik A, Anisiewicz A, Filip-Psurska B, Klopotowska D, Maciejewska M, Mazur A, Wietrzyk J. Divergent effect of tacalcitol (PRI-2191) on Th17 cells in 4T1 tumor bearing young and old ovariectomized mice. Aging Dis. 2020;11(2):241.PubMedPubMedCentralCrossRef
109.
Yu L-Y, Tang J, Zhang C-M, Zeng W-J, Yan H, Li M-P, Chen X-P. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14(1):68.PubMedCentralCrossRef
110.
Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, Azizi G, Baradaran B. The paradox of Th17 cell functions in tumor immunity. Cell Immunol. 2017;322:15–25.PubMedCrossRef
111.
Joshi N, Hajizadeh F, Dezfouli EA, Zekiy AO, Afjadi MN, Mousavi SM, Hojjat-Farsangi M, Karpisheh V, Mahmoodpoor A, Hassannia H. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sci. 2021;275:119369.PubMedCrossRef
112.
Amedei A, Munari F, Della Bella C, Niccolai E, Benagiano M, Bencini L, Cianchi F, Farsi M, Emmi G, Zanotti G. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Intern Emerg Med. 2014;9(3):303–9.PubMedCrossRef
113.
Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, Dalod M, Soumelis V, Amigorena S. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity. 2013;38(2):336–48.PubMedCrossRef
Metadata
Title
The role of Th17 cells in the pathogenesis and treatment of breast cancer
Authors
Vahid Karpisheh
Majid Ahmadi
Kazem Abbaszadeh-Goudarzi
Mehran Mohammadpour Saray
Asal Barshidi
Hamed Mohammadi
Mehdi Yousefi
Farhad Jadidi-Niaragh
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02528-8

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Research

METTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10

Review

miR-1908: a microRNA with diverse functions in cancers and non-malignant conditions

Research

Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression

Primary research

SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways

Research

Establishment of anti-DKK3 peptide for the cancer control in head and neck squamous cell carcinoma (HNSCC)

Research

Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits